Items Tagged ‘News’

An interim analyses of the phase 3 “ASCEND” clinical trial evaluating single-agent Calquence (acalabrutinib) compared to Rituxan (rituximab) plus idelasib or bendamustine in recurrent chronic lymphocytic leukemia (CLL) is closed early due to favorable results. (1) About chronic lymphocytic leukemia CLL is the most common type of leukemia in adults. (2) with an average age […]

Zytig (Abiraterone acetate) plus prednisone and androgen deprivation therapy (ADT) significantly extends overall survival compared with placebo plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (CSPC) About Zytig Zytiga is an oral targeted agent that blocks the production of androgens (male hormones such as testosterone) not only by the testes, but […]

On May 2, 2019, the Food and Drug Administration approved ivosidenib (TIBSOVO, Agios Pharmaceuticals, Inc.) for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy. Approval was […]

One year of IV Herceptin (trastuzumab) is the standard of care for women with HER2-positive early stage breast cancer (ESBC). Doctors from Germany have confirmed that Herceptin can safely be administered subcutaneously without compromising effectiveness – increasing patient convenience. Dr. Jackisch M.D. and colleagues reported the results of an open-label, multi-center, international clinical trial to […]

A new study in the April 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network reports that oral cryotherapy reduce mucositis related side effects. Ice chips or “cryotherapy” has long been used to reduce the intensity of mouth sores called mucositis that occur following treatment with stem cell transplant and certain chemotherapy drugs. This current study enrolled 50 […]

The American Society of Clinical Oncology (ASCO) has released a new guideline that states that patients with clinically low-risk stage III colon cancer should have the option of receiving 3 months of adjuvant oxaliplatin-based chemotherapy. For patients at a high risk of recurrence (T4 and/or N2), adjuvant chemotherapy should be offered for a duration of […]

According to the National Cancer Institute the overall results of studies designed to compare dose dense therapy to every 3 week therapy support the use of dose-dense chemotherapy for the treatment of women with HER2-negative early stage breast cancer (ESBC).(1) In the United States “dose dense” chemotherapy is considered standard of care for the treatment […]

granted accelerated approval to Balversa (erdafitinib) for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Today, […]

Women who are not at high risk for breast cancer can wait to start getting mammograms until age 50 and be screened every other year, according to new guidelines from the American College of Physicians. Women at high risk for breast cancer are those with a family history of breast cancer, previous cancer scares, dense […]

Giving chemotherapy drugs every two weeks instead of every three weeks reduces the risk of breast cancer recurrence and death in women undergoing adjuvant chemotherapy for early stage breast cancer. The analyses was performed by British physicians in the Early Breast Cancer Trialists Collaborative Group who evaluated 37,000 women who participated in 26 clinical trials […]

A new combination of immunotherapy and chemotherapy for pancreatic cancer caused tumors to shrink in the majority of evaluable patients – 20 out of 24 as of an interim analysis of the phase 1b trial data. The early findings provide hope that this strategy involving a CD40 antibody, a checkpoint inhibitor, and standard-of-care chemotherapy could […]

An early phase clinical trial evaluating dostarlimab in women with recurrent or advanced endometrial cancer appears promising. These data were presented at the 2019 Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in Honolulu, Hawaii. Endometrial cancer (EC) is the most common gynaecologic malignancy in the U.S. but there are limited treatment options […]

The NCCN has recently updated its ovarian cancer treatment guidelines and make the following significant changes. All patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer should have a genetic risk evaluation and BRCA1/2 testing performed. Maintenance Therapy: Lynparza (olaparib) was added as a maintenance therapy option after complete or partial clinical remission […]

PHILADELPHIA, PA– Prophylactic cranial irradiation (PCI), a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer (SCLC) after initial therapy. While studies established that PCI decreases the incidence of brain metastases for patients with locally advanced non-small cell lung cancer […]

Lynparza (olaparib) improves progression-free survival (PFS) when used to treat BRCA-mutated pancreatic cancer and appears to represent a new treatment option for this hard to treat cancer. (1-4) About BRCA Mutated Pancreatic Cancer Pancreatic cancer has the worst survival rate of the most common cancers and less than seven percent of patients survive more than […]